To use our website in an optimal way, please activate JavaScript in your Browser.

J Musculoskelet Neuronal Interact, 2022; 22(1): 70-78, PMID: 35234161

The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Year: 2022

Chinoy A, Vassallo GR, Burkitt Wright E, Eelloo J, West S, Hupton E, Galloway P, Pilkington A, Padidela R, Mughal MZ
Department of Paediatric Endocrinology, Royal Manchester Children"s Hospital, Manchester University NHS Foundation Trust, Manchester, UK.


Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children with NF1 are unable to undertake physical activities to the same level as their peers, and report leg pains on physical activity and aching hands on writing. Children and adolescents with NF1 reporting symptoms of muscle weakness should have a focused assessment to exclude alternative causes of muscle weakness. Assessments of muscle strength and fine motor skills by physiotherapists and occupational therapists can provide objective evidence of muscle function and deficits, allowing supporting systems in education and at home to be implemented. In the absence of an evidence base for management of NF1-related muscle weakness, we recommend muscle-strengthening exercises and generic strategies for pain and fatigue management. Currently, trials are underway involving whole-body vibration therapy and carnitine supplementation as potential future management options.

GID: 5651; Last update: 07.03.2022